RCKT Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
51.0M
+8.6%
46.9M
-3.3%
48.5M
+10.3%
44.0M
-15.9%
52.2M
R&D
31.2M
+5.7%
29.5M
-6.2%
31.5M
+7.2%
29.3M
-13.9%
34.1M
SG&A
19.8M
+13.6%
17.4M
+2.2%
17.1M
+16.2%
14.7M
-20.0%
18.4M
Operating Income
-50965000
-8.6%
-46922000
+3.3%
-48511000
-10.3%
-43963000
+15.9%
-52247000
EBITDA
-49474000
-9.1%
-45358000
+3.3%
-46903000
-10.7%
-42353000
+14.8%
-49717000
Net Income
-49234000
-140.0%
123.2M
+352.4%
-48823000
-14.8%
-42538000
+15.5%
-50332000
EPS (Basic)
$-0.43
-139.4%
$1.09
+359.5%
$-0.42
-10.5%
$-0.38
+15.6%
$-0.45
EPS (Diluted)
$-0.43
-139.8%
$1.08
+357.1%
$-0.42
-10.5%
$-0.38
+15.6%
$-0.45
Shares (Diluted)
113.6M
-0.8%
114.5M
+2.1%
112.1M
+0.3%
111.8M
+0.2%
111.6M
Rocket Pharmaceuticals (RCKT) — Financials